content: <html>
  
  <head>
  
  
  
  
  
  </head>
  
  <body lang="EN-US">
  
  <div style="font-family:Times New Roman;">
  
  <div style="border:none;border-top:double windowtext 6.0pt;padding:0in 0in 0in 0in;">
  
  <p style="border:none;margin:0in 0in .0001pt;padding:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  </div>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">UNITED STATES<br>
  </font></b><b><font size="5" style="font-size:18.0pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></b></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Washington
  D.C. 20549</font></b></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">FORM&nbsp;8-K</font></b></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;">CURRENT
  REPORT</font></b></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;">PURSUANT
  TO SECTION&nbsp;13 OR 15(d)&nbsp;OF</font></b></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;">THE
  SECURITIES EXCHANGE ACT OF 1934</font></b></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date of Report:<b> April&nbsp;24, 2008</b></font></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Date of Earliest
  Event Reported)</font></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">Clarient,&nbsp;Inc.</font></b></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Exact Name of
  Registrant as Specified in Its Charter)</font></p>
  
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <div align="center">
  
  <table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
   <tr>
    <td width="32%" valign="top" style="padding:0in .7pt 0in .7pt;width:32.0%;">
    <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Delaware</font></b></p>
    </td>
    <td width="2%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:2.0%;">
    <p style="margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
    </td>
    <td width="32%" valign="top" style="padding:0in .7pt 0in .7pt;width:32.0%;">
    <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">000-22677</font></b></p>
    </td>
    <td width="2%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:2.0%;">
    <p style="margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
    </td>
    <td width="32%" valign="top" style="padding:0in .7pt 0in .7pt;width:32.0%;">
    <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">75-2649072</font></b></p>
    </td>
   </tr>
   <tr>
    <td width="32%" valign="top" style="padding:0in .7pt 0in .7pt;width:32.0%;">
    <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(State or Other
    Jurisdiction</font></p>
    </td>
    <td width="2%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:2.0%;">
    <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
    </td>
    <td width="32%" valign="top" style="padding:0in .7pt 0in .7pt;width:32.0%;">
    <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Commission</font></p>
    </td>
    <td width="2%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:2.0%;">
    <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
    </td>
    <td width="32%" valign="top" style="padding:0in .7pt 0in .7pt;width:32.0%;">
    <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(I.R.S. Employer</font></p>
    </td>
   </tr>
   <tr>
    <td width="32%" valign="top" style="padding:0in .7pt 0in .7pt;width:32.0%;">
    <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">of
    Incorporation)</font></p>
    </td>
    <td width="2%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:2.0%;">
    <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
    </td>
    <td width="32%" valign="top" style="padding:0in .7pt 0in .7pt;width:32.0%;">
    <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">File Number)</font></p>
    </td>
    <td width="2%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:2.0%;">
    <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
    </td>
    <td width="32%" valign="top" style="padding:0in .7pt 0in .7pt;width:32.0%;">
    <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Identification
    No.)</font></p>
    </td>
   </tr>
   <tr>
    <td width="32%" valign="top" style="padding:0in .7pt 0in .7pt;width:32.0%;">
    <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
    </td>
    <td width="2%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:2.0%;">
    <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
    </td>
    <td width="32%" valign="top" style="padding:0in .7pt 0in .7pt;width:32.0%;">
    <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
    </td>
    <td width="2%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:2.0%;">
    <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
    </td>
    <td width="32%" valign="top" style="padding:0in .7pt 0in .7pt;width:32.0%;">
    <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
    </td>
   </tr>
   <tr>
    <td width="66%" colspan="3" valign="top" style="padding:0in .7pt 0in .7pt;width:66.0%;">
    <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">31
    Columbia, Aliso Viejo, California</font></b></p>
    </td>
    <td width="2%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:2.0%;">
    <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
    </td>
    <td width="32%" valign="top" style="padding:0in .7pt 0in .7pt;width:32.0%;">
    <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">92656</font></b></p>
    </td>
   </tr>
   <tr>
    <td width="66%" colspan="3" valign="top" style="padding:0in .7pt 0in .7pt;width:66.0%;">
    <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Address of
    Principal Executive Offices)</font></p>
    </td>
    <td width="2%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:2.0%;">
    <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
    </td>
    <td width="32%" valign="top" style="padding:0in .7pt 0in .7pt;width:32.0%;">
    <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Zip Code)</font></p>
    </td>
   </tr>
  </table>
  
  </div>
  
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(949)
  425-5700</font></b></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Registrant&#146;s
  Telephone Number, Including Area Code)</font></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">N/A</font></b></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Former Name or
  Former Address, if Changed Since Last Report)</font></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Check the appropriate box below if the Form&nbsp;8-K
  filing is intended to simultaneously satisfy the filing obligation of the
  registrant under any of the following provisions:</font></p>
  
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="margin:0in 0in .0001pt .5in;text-autospace:none;text-indent:-.5in;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Written communications pursuant to Rule&nbsp;425 under
  the Securities Act (17 CFR 230.425)</font></p>
  
  <p style="margin:0in 0in .0001pt .5in;text-autospace:none;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="margin:0in 0in .0001pt .5in;text-autospace:none;text-indent:-.5in;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Soliciting material pursuant to Rule&nbsp;14a-12 under
  the Exchange Act (17 CFR 240.14a-12)</font></p>
  
  <p style="margin:0in 0in .0001pt .5in;text-autospace:none;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="margin:0in 0in .0001pt .5in;text-autospace:none;text-indent:-.5in;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Pre-commencement communications pursuant to Rule&nbsp;14d-2(b)&nbsp;under
  the Exchange Act (17 CFR 240.14d-2(b))</font></p>
  
  <p style="margin:0in 0in .0001pt .5in;text-autospace:none;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="margin:0in 0in .0001pt .5in;text-autospace:none;text-indent:-.5in;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Pre-commencement communications pursuant to Rule&nbsp;13e-4(c)&nbsp;under
  the Exchange Act (17 CFR 240.13e-4(c))</font></p>
  
  <div style="border:none;border-bottom:double windowtext 6.0pt;padding:0in 0in 0in 0in;">
  
  <p style="border:none;margin:0in 0in .0001pt .5in;padding:0in;text-autospace:none;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  </div>
  
  <p style="margin:0in 0in .0001pt .5in;text-autospace:none;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <div style="margin:0in 0in .0001pt;text-autospace:none;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
  
  </div>
  <!-- SEQ.=1,FOLIO='',FILE='C:\JMS\eudelhofen\08-12781-1\task2899254\12781-1-ba.htm',USER='eudelho',CD='Apr 28 15:19 2008' -->
  
  
  <br clear="all" style="page-break-before:always;">
  
  
  <div>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 1.01&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Entry into a Material Definitive Agreement.</font></b></p>
  
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="margin:0in 0in .0001pt;text-autospace:none;text-indent:.5in;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Employment
  Agreement with Michael J. Pellini, M.D.</font></i></b></p>
  
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="margin:0in 0in .0001pt;text-autospace:none;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On April&nbsp;24, 2008, Clarient,&nbsp;Inc.
  (the &#147;Company&#148;) entered into an employment agreement with Michael J. Pellini,
  pursuant to which Dr.&nbsp;Pellini will become a full time employee of the
  Company and serve as President and Chief Operating Officer of the Company,
  effective as of April&nbsp;24, 2008. Under the terms of the agreement, Dr.&nbsp;Pellini
  will receive a base salary of $283,250 per year and options to purchase 400,000
  shares of common stock of the Company. The options will vest 25% on the first
  anniversary of the grant date and in 36 equal monthly installments thereafter
  (subject to acceleration in the event of a change of control) and have an
  exercise price equal to the fair market value of the Company&#146;s common stock on
  the date of grant. In addition, Dr.&nbsp;Pellini will participate in the
  Company&#146;s Management Incentive Plan and will be eligible for a target incentive
  bonus of 60% of base salary based on achievement of Company and personal
  objectives. Dr.&nbsp;Pellini is also entitled to certain perquisites, such as
  an automobile allowance, matching contributions under a voluntary savings plan,
  a monthly $8,000 housing allowance (grossed up to the extent of taxes payable
  by Dr.&nbsp;Pellini with respect thereto), and other benefits generally
  available to the Company&#146;s executives.</font></p>
  
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="margin:0in 0in .0001pt;text-autospace:none;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Subject to executing a
  general release of the Company, Dr.&nbsp;Pellini will be entitled to receive
  severance payments in the event his employment is terminated (i)&nbsp;by the
  Company without cause, (ii)&nbsp;by him with good reason within 12 months of a
  change of control of the Company, or (iii)&nbsp;as a result of his death or
  disability (any of the foregoing, a &#147;Severance Termination&#148;). Such severance
  payments will consist of payment of 12 months&#146; base salary (based on the base
  salary in effect at the time of termination), as well as continued coverage
  under the Company&#146;s medical and health plans, and all options that are exercisable
  on or before the termination date will remain exercisable until the earlier of
  the first anniversary of his date of termination or the expiration date of the
  options. In the event that Dr.&nbsp;Pellini remains employed by the Company
  through April&nbsp;24, 2009 or experiences a Severance Termination prior to April&nbsp;24,
  2009 and, in either case, within one year following the date of termination,
  either (i)&nbsp;a change of control of the Company occurs or (ii)&nbsp;the
  Company enters into a definitive agreement pursuant to which, if consummated, a
  change of control would occur and no later than eighteen months following the
  date of termination a change of control occurs, all unvested options held by Dr.&nbsp;Pellini
  will become fully vested and exercisable immediately prior to the occurrence of
  any such change of control. The agreement also provides that, if Dr.&nbsp;Pellini&#146;s
  employment is terminated without cause (i)&nbsp;prior to April&nbsp;1, 2009,
  the Company will continue to pay his monthly housing allowance until July&nbsp;1,
  2009, or (ii)&nbsp;after April&nbsp;1, 2009, the Company will continue to pay his
  monthly housing allowance until the earlier of three months after termination
  or August&nbsp;31, 2009, in each case to the extent of his actual housing
  expenses in California that he is not able to mitigate. In the event of
  termination of Dr.&nbsp;Pellini&#146;s employment for any reason, he will be
  entitled to receive all accrued, unpaid salary to the date of termination and a
  pro rata portion of his bonus for the year of termination</font></p>
  
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="margin:0in 0in .0001pt;text-autospace:none;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company issued a
  press release announcing Dr.&nbsp;Pellini&#146;s appointment, a copy of which is
  attached to this Current Report on Form&nbsp;8-K as Exhibit&nbsp;99.1. The
  information set forth above is qualified in its entirety by reference to Dr.&nbsp;Pellini&#146;s
  employment agreement attached hereto as Exhibit&nbsp;10.1, which exhibit is
  incorporated herein by reference.</font></p>
  
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 1.02&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Termination of a Material Definitive Agreement.</font></b></p>
  
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="margin:0in 0in .0001pt;text-autospace:none;text-indent:.5in;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Termination
  of Services Agreement with Michael J. Pellini, M.D.</font></i></b></p>
  
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="margin:0in 0in .0001pt;text-autospace:none;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Dr.&nbsp;Pellini&#146;s
  employment agreement supersedes the Services Agreement entered into on October&nbsp;1,
  2007 by and between the Company, Safeguard Scientifics (the Company&#146;s majority
  stockholder) and Dr.&nbsp;Pellini (the &#147;Services Agreement&#148;). &#160;Dr.&nbsp;Pellini had been providing services
  to the Company while remaining an employee of Safeguard pursuant to the
  Services Agreement.&#160; Under the terms of
  the Services Agreement, in exchange for Safeguard making the services of Dr.&nbsp;Pellini
  available to the Company, the Company reimbursed Safeguard for the following
  expenses incurred by Safeguard during Dr.&nbsp;Pellini&#146;s tenure with the
  Company during the term of the Services Agreement (with retroactive effect to September&nbsp;4,
  2007): (i)&nbsp;Dr.&nbsp;Pellini&#146;s base salary at an annualized rate of
  $250,000 (subject to increase commensurate with salary increases applicable to the
  Company&#146;s executives generally); (ii)&nbsp;the lesser of (A)&nbsp;the annual
  bonus to which Dr.&nbsp;Pellini would have become entitled as an employee of
  the Company, and (B)&nbsp;the annual bonus actually paid to Dr.&nbsp;Pellini </font></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2</font></p>
  
  <div style="margin:0in 0in .0001pt;text-autospace:none;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
  
  </div>
  <!-- SEQ.=1,FOLIO='2',FILE='C:\JMS\eudelhofen\08-12781-1\task2899254\12781-1-ba.htm',USER='eudelho',CD='Apr 28 15:19 2008' -->
  
  
  <br clear="all" style="page-break-before:always;">
  
  
  <div style="font-family:Times New Roman;">
  
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">by Safeguard (pro-rated for any partial calendar
  year); and (iii)&nbsp;certain other expenses associated with Dr.&nbsp;Pellini&#146;s
  employment by Safeguard and his provision of services to the Company in
  California.</font></p>
  
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="margin:0in 0in .0001pt 1.0in;text-autospace:none;text-indent:-1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item
  5.02</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Departure of Directors
  or Certain Officers; Election of Directors; Appointment of Certain Officers;
  Compensatory Arrangements of Certain Officers.</font></b></p>
  
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="margin:0in 0in .0001pt;text-autospace:none;text-indent:.5in;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Michael J.
  Pellini, M.D. Appointed as President of the Company</font></i></b></p>
  
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="margin:0in 0in .0001pt;text-autospace:none;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On
  April&nbsp;24, 2008, Ronald A. Andrews, the Company&#146;s Chief Executive Officer,
  was appointed to serve as Vice Chairman of the Company&#146;s Board of Directors (in
  addition to his title as Chief Executive Officer) and Michael J. Pellini was
  appointed to serve as the Company&#146;s President (in addition to his title of
  Chief Operating Officer). Mr.&nbsp;Andrews resigned as President of the Company
  on such date, but will continue to serve as Chief Executive Officer of the
  Company. In addition, both Mr.&nbsp;Andrews and Dr.&nbsp;Pellini will continue
  to serve on the Company&#146;s Board of Directors.</font></p>
  
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="margin:0in 0in .0001pt;text-autospace:none;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Dr.&nbsp;Pellini,
  42, has served on the Company&#146;s Board of Directors since 2007. Dr.&nbsp;Pellini
  was previously the Vice President of the Life Sciences Group at Safeguard from February&nbsp;2007
  until April&nbsp;2008. Prior to joining Safeguard, Dr.&nbsp;Pellini was Chief
  Operating Officer for Lakewood Pathology Associates,&nbsp;Inc., a national
  anatomical pathology company (April&nbsp;2005 to December&nbsp;2006);
  Entrepreneur in Residence at BioAdvance, the Biotechnology Greenhouse of
  Southeastern Pennsylvania (September&nbsp;2004 to April&nbsp;2005); and
  President and Chief Executive Officer of Genomics Collaborative,&nbsp;Inc., a
  Boston-based biotech firm which was acquired by SeraCare Life Sciences,&nbsp;Inc.
  in 2004 (June&nbsp;1999 to February&nbsp;2004). Dr.&nbsp;Pellini received a
  B.A. degree from Boston College, an MBA degree from Drexel University, and an
  M.D. degree from Jefferson Medical College of Thomas Jefferson University.</font></p>
  
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="margin:0in 0in .0001pt;text-autospace:none;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">A
  description of the material terms of Dr.&nbsp;Pellini&#146;s employment agreement
  with the Company is set forth under Item 1.01 above.</font></p>
  
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 9.01&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Financial Statements and Exhibits.</font></b></p>
  
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
   <tr>
    <td width="18%" valign="top" style="padding:0in .7pt 0in .7pt;width:18.16%;">
    <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Exhibit&nbsp;10.1</font></p>
    </td>
    <td width="81%" valign="top" style="padding:0in .7pt 0in .7pt;width:81.84%;">
    <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Employment Agreement, dated as of April&nbsp;24,
    2008, by and between Clarient,&nbsp;Inc. and Michael J. Pellini.</font></p>
    </td>
   </tr>
   <tr>
    <td width="18%" valign="top" style="padding:0in .7pt 0in .7pt;width:18.16%;">
    <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
    </td>
    <td width="81%" valign="top" style="padding:0in .7pt 0in .7pt;width:81.84%;">
    <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
    </td>
   </tr>
   <tr>
    <td width="18%" valign="top" style="padding:0in .7pt 0in .7pt;width:18.16%;">
    <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Exhibit&nbsp;99.1</font></p>
    </td>
    <td width="81%" valign="top" style="padding:0in .7pt 0in .7pt;width:81.84%;">
    <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Press release, dated April&nbsp;28, 2008, issued by
    Clarient,&nbsp;Inc. announcing appointment of Michael J. Pellini as
    President.</font></p>
    </td>
   </tr>
  </table>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3</font></p>
  
  <div style="margin:0in 0in .0001pt;text-autospace:none;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
  
  </div>
  <!-- SEQ.=1,FOLIO='3',FILE='C:\JMS\eudelhofen\08-12781-1\task2899254\12781-1-ba.htm',USER='eudelho',CD='Apr 28 15:19 2008' -->
  
  
  <br clear="all" style="page-break-before:always;">
  
  
  <div>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SIGNATURE</font></b></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="margin:0in 0in .0001pt;text-autospace:none;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Pursuant to the
  requirements of the Securities Exchange Act of 1934, the registrant has duly
  caused this report to be signed on its behalf by the undersigned hereunto duly
  authorized.</font></p>
  
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
   <tr>
    <td width="49%" valign="top" style="padding:0in .7pt 0in .7pt;width:49.84%;">
    <p style="margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
    </td>
    <td width="50%" colspan="2" valign="top" style="padding:0in .7pt 0in .7pt;width:50.16%;">
    <p style="margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Clarient,&nbsp;Inc.</font></b></p>
    </td>
   </tr>
   <tr>
    <td width="49%" valign="top" style="padding:0in .7pt 0in .7pt;width:49.84%;">
    <p style="margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
    </td>
    <td width="50%" colspan="2" valign="top" style="padding:0in .7pt 0in .7pt;width:50.16%;">
    <p style="margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
    </td>
   </tr>
   <tr>
    <td width="49%" valign="top" style="padding:0in .7pt 0in .7pt;width:49.84%;">
    <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date: April&nbsp;28, 2008</font></p>
    </td>
    <td width="7%" valign="top" style="padding:0in .7pt 0in .7pt;width:7.64%;">
    <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>
    </td>
    <td width="42%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in .7pt 0in .7pt;width:42.52%;">
    <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ James V. Agnello</font></p>
    </td>
   </tr>
   <tr>
    <td width="49%" valign="top" style="padding:0in .7pt 0in .7pt;width:49.84%;">
    <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
    </td>
    <td width="7%" valign="top" style="padding:0in .7pt 0in .7pt;width:7.64%;">
    <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>
    </td>
    <td width="42%" valign="top" style="padding:0in .7pt 0in .7pt;width:42.52%;">
    <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">James V. Agnello</font></p>
    </td>
   </tr>
   <tr>
    <td width="49%" valign="top" style="padding:0in .7pt 0in .7pt;width:49.84%;">
    <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
    </td>
    <td width="7%" valign="top" style="padding:0in .7pt 0in .7pt;width:7.64%;">
    <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:</font></p>
    </td>
    <td width="42%" valign="top" style="padding:0in .7pt 0in .7pt;width:42.52%;">
    <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Senior Vice President and Chief Financial Officer</font></p>
    </td>
   </tr>
   <tr>
    <td width="49%" valign="top" style="padding:0in .7pt 0in .7pt;width:49.84%;">
    <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
    </td>
    <td width="7%" valign="top" style="padding:0in .7pt 0in .7pt;width:7.64%;">
    <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
    </td>
    <td width="42%" valign="top" style="padding:0in .7pt 0in .7pt;width:42.52%;">
    <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
    </td>
   </tr>
  </table>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4</font></p>
  
  <div style="margin:0in 0in .0001pt;text-autospace:none;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
  
  </div>
  <!-- SEQ.=1,FOLIO='4',FILE='C:\JMS\eudelhofen\08-12781-1\task2899254\12781-1-ba.htm',USER='eudelho',CD='Apr 28 15:19 2008' -->
  
  
  </body>
  
  </html>
metadata_documents: [{"type": "8-K", "sequence": "1", "filename": "a08-12781_18k.htm", "description": "8-K", "secsgml_size_bytes": 37290}]
metadata_filer: {"company-data": {"conformed-name": "CLARIENT, INC", "cik": "0001038223", "assigned-sic": "3826", "irs-number": "752649072", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-22677", "film-number": "08781910"}, "business-address": {"street1": "31 COLUMBIA", "city": "ALISO VIEJO", "state": "CA", "zip": "92656", "phone": "949 425-5865"}, "mail-address": {"street1": "31 COLUMBIA", "city": "ALISO VIEJO", "state": "CA", "zip": "92656"}, "former-company": {"former-conformed-name": "CHROMAVISION MEDICAL SYSTEMS INC", "date-changed": "19970423"}}
text: UNITED STATES
  SECURITIES AND EXCHANGE COMMISSION
  Washington
  D.C. 20549
  FORM 8-K
  CURRENT
  REPORT
  PURSUANT
  TO SECTION 13 OR 15(d) OF
  THE
  SECURITIES EXCHANGE ACT OF 1934
  Date of Report:
  April 24, 2008
  (Date of Earliest
  Event Reported)
  Clarient, Inc.
  (Exact Name of
  Registrant as Specified in Its Charter)
  Delaware
  000-22677
  75-2649072
  (State or Other
    Jurisdiction
  (Commission
  (I.R.S. Employer
  of
    Incorporation)
  File Number)
  Identification
    No.)
  31
    Columbia, Aliso Viejo, California
  92656
  (Address of
    Principal Executive Offices)
  (Zip Code)
  (949)
  425-5700
  (Registrant's
  Telephone Number, Including Area Code)
  N/A
  (Former Name or
  Former Address, if Changed Since Last Report)
  Check the appropriate box below if the Form 8-K
  filing is intended to simultaneously satisfy the filing obligation of the
  registrant under any of the following provisions:
  o
  Written communications pursuant to Rule 425 under
  the Securities Act (17 CFR 230.425)
  o
  Soliciting material pursuant to Rule 14a-12 under
  the Exchange Act (17 CFR 240.14a-12)
  o
  Pre-commencement communications pursuant to Rule 14d-2(b) under
  the Exchange Act (17 CFR 240.14d-2(b))
  o
  Pre-commencement communications pursuant to Rule 13e-4(c) under
  the Exchange Act (17 CFR 240.13e-4(c))
  Item 1.01               Entry into a Material Definitive Agreement.
  Employment
  Agreement with Michael J. Pellini, M.D.
  On April 24, 2008, Clarient, Inc.
  (the "Company") entered into an employment agreement with Michael J. Pellini,
  pursuant to which Dr. Pellini will become a full time employee of the
  Company and serve as President and Chief Operating Officer of the Company,
  effective as of April 24, 2008. Under the terms of the agreement, Dr. Pellini
  will receive a base salary of $283,250 per year and options to purchase 400,000
  shares of common stock of the Company. The options will vest 25% on the first
  anniversary of the grant date and in 36 equal monthly installments thereafter
  (subject to acceleration in the event of a change of control) and have an
  exercise price equal to the fair market value of the Company's common stock on
  the date of grant. In addition, Dr. Pellini will participate in the
  Company's Management Incentive Plan and will be eligible for a target incentive
  bonus of 60% of base salary based on achievement of Company and personal
  objectives. Dr. Pellini is also entitled to certain perquisites, such as
  an automobile allowance, matching contributions under a voluntary savings plan,
  a monthly $8,000 housing allowance (grossed up to the extent of taxes payable
  by Dr. Pellini with respect thereto), and other benefits generally
  available to the Company's executives.
  Subject to executing a
  general release of the Company, Dr. Pellini will be entitled to receive
  severance payments in the event his employment is terminated (i) by the
  Company without cause, (ii) by him with good reason within 12 months of a
  change of control of the Company, or (iii) as a result of his death or
  disability (any of the foregoing, a "Severance Termination"). Such severance
  payments will consist of payment of 12 months' base salary (based on the base
  salary in effect at the time of termination), as well as continued coverage
  under the Company's medical and health plans, and all options that are exercisable
  on or before the termination date will remain exercisable until the earlier of
  the first anniversary of his date of termination or the expiration date of the
  options. In the event that Dr. Pellini remains employed by the Company
  through April 24, 2009 or experiences a Severance Termination prior to April 24,
  2009 and, in either case, within one year following the date of termination,
  either (i) a change of control of the Company occurs or (ii) the
  Company enters into a definitive agreement pursuant to which, if consummated, a
  change of control would occur and no later than eighteen months following the
  date of termination a change of control occurs, all unvested options held by Dr. Pellini
  will become fully vested and exercisable immediately prior to the occurrence of
  any such change of control. The agreement also provides that, if Dr. Pellini's
  employment is terminated without cause (i) prior to April 1, 2009,
  the Company will continue to pay his monthly housing allowance until July 1,
  2009, or (ii) after April 1, 2009, the Company will continue to pay his
  monthly housing allowance until the earlier of three months after termination
  or August 31, 2009, in each case to the extent of his actual housing
  expenses in California that he is not able to mitigate. In the event of
  termination of Dr. Pellini's employment for any reason, he will be
  entitled to receive all accrued, unpaid salary to the date of termination and a
  pro rata portion of his bonus for the year of termination
  The Company issued a
  press release announcing Dr. Pellini's appointment, a copy of which is
  attached to this Current Report on Form 8-K as Exhibit 99.1. The
  information set forth above is qualified in its entirety by reference to Dr. Pellini's
  employment agreement attached hereto as Exhibit 10.1, which exhibit is
  incorporated herein by reference.
  Item 1.02               Termination of a Material Definitive Agreement.
  Termination
  of Services Agreement with Michael J. Pellini, M.D.
  Dr. Pellini's
  employment agreement supersedes the Services Agreement entered into on October 1,
  2007 by and between the Company, Safeguard Scientifics (the Company's majority
  stockholder) and Dr. Pellini (the "Services Agreement").  Dr. Pellini had been providing services
  to the Company while remaining an employee of Safeguard pursuant to the
  Services Agreement.  Under the terms of
  the Services Agreement, in exchange for Safeguard making the services of Dr. Pellini
  available to the Company, the Company reimbursed Safeguard for the following
  expenses incurred by Safeguard during Dr. Pellini's tenure with the
  Company during the term of the Services Agreement (with retroactive effect to September 4,
  2007): (i) Dr. Pellini's base salary at an annualized rate of
  $250,000 (subject to increase commensurate with salary increases applicable to the
  Company's executives generally); (ii) the lesser of (A) the annual
  bonus to which Dr. Pellini would have become entitled as an employee of
  the Company, and (B) the annual bonus actually paid to Dr. Pellini
  2
  by Safeguard (pro-rated for any partial calendar
  year); and (iii) certain other expenses associated with Dr. Pellini's
  employment by Safeguard and his provision of services to the Company in
  California.
  Item
  5.02
  Departure of Directors
  or Certain Officers; Election of Directors; Appointment of Certain Officers;
  Compensatory Arrangements of Certain Officers.
  Michael J.
  Pellini, M.D. Appointed as President of the Company
  On
  April 24, 2008, Ronald A. Andrews, the Company's Chief Executive Officer,
  was appointed to serve as Vice Chairman of the Company's Board of Directors (in
  addition to his title as Chief Executive Officer) and Michael J. Pellini was
  appointed to serve as the Company's President (in addition to his title of
  Chief Operating Officer). Mr. Andrews resigned as President of the Company
  on such date, but will continue to serve as Chief Executive Officer of the
  Company. In addition, both Mr. Andrews and Dr. Pellini will continue
  to serve on the Company's Board of Directors.
  Dr. Pellini,
  42, has served on the Company's Board of Directors since 2007. Dr. Pellini
  was previously the Vice President of the Life Sciences Group at Safeguard from February 2007
  until April 2008. Prior to joining Safeguard, Dr. Pellini was Chief
  Operating Officer for Lakewood Pathology Associates, Inc., a national
  anatomical pathology company (April 2005 to December 2006);
  Entrepreneur in Residence at BioAdvance, the Biotechnology Greenhouse of
  Southeastern Pennsylvania (September 2004 to April 2005); and
  President and Chief Executive Officer of Genomics Collaborative, Inc., a
  Boston-based biotech firm which was acquired by SeraCare Life Sciences, Inc.
  in 2004 (June 1999 to February 2004). Dr. Pellini received a
  B.A. degree from Boston College, an MBA degree from Drexel University, and an
  M.D. degree from Jefferson Medical College of Thomas Jefferson University.
  A
  description of the material terms of Dr. Pellini's employment agreement
  with the Company is set forth under Item 1.01 above.
  Item 9.01               Financial Statements and Exhibits.
  Exhibit 10.1
  Employment Agreement, dated as of April 24,
    2008, by and between Clarient, Inc. and Michael J. Pellini.
  Exhibit 99.1
  Press release, dated April 28, 2008, issued by
    Clarient, Inc. announcing appointment of Michael J. Pellini as
    President.
  3
  SIGNATURE
  Pursuant to the
  requirements of the Securities Exchange Act of 1934, the registrant has duly
  caused this report to be signed on its behalf by the undersigned hereunto duly
  authorized.
  Clarient, Inc.
  Date: April 28, 2008
  By:
  /s/ James V. Agnello
  Name:
  James V. Agnello
  Title:
  Senior Vice President and Chief Financial Officer
  4